Results 261 to 270 of about 88,356 (287)
Some of the next articles are maybe not open access.
Antibody-Drug Conjugate Targets
Current Cancer Drug Targets, 2009The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire +2 more sources
Antibody-Drug Conjugates in Urothelial Carcinomas
Current Oncology Reports, 2020Urothelial carcinoma (UC) is a common malignancy with an urgent need for more effective and less toxic treatment strategies. Antibody-drug conjugate (ADC) represents a novel therapeutic approach, which combines the high specificity of monoclonal antibodies covalently linked with highly active cytotoxic agents.
Michal, Sarfaty, Jonathan E, Rosenberg
openaire +2 more sources
Antibody-drug conjugates for multiple myeloma
Expert Opinion on Biological Therapy, 2020Introduction: Antibody-drug conjugates (ADC) are a new class of treatment for multiple myeloma (MM) patients, delivering a potent cytotoxic agent directly to the myeloma cell. The target is defined by the specificity of the monoclonal antibody which is linked to the cytotoxic agent.
Annabel McMillan +2 more
openaire +2 more sources
Payloads of Antibody: Drug Conjugates
2015The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire +1 more source
Antibody-Drug Conjugates for Cancer Therapy
The Cancer Journal, 2008The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug selectively to a target such as a tumor-associated antigen. Such conjugates represent a broadly applicable approach to enhance the antitumor activity of antibodies and improve the tumor-to-normal tissue selectivity of chemotherapy.
Paul J, Carter, Peter D, Senter
openaire +2 more sources
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Expert Opinion on Biological Therapy, 2020David M Goldenberg, Robert M Sharkey
exaly